At its meeting of 06 February 2023, the Transparency Council adopted Position No. 15/2023 on the evaluation of the medicine Findarts Duo (dutasteride + tamsulosin hydrochloride) for the indication: treatment of moderate to severe symptoms of benign prostatic hyperplasia.